MOUNTAIN VIEW, Calif., Sept. 4, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI ), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.
- Morgan Stanley Global Healthcare Unplugged Conference, Grand Hyatt New York Hotel, New York, NY
- Wednesday, September 11, 2013, at 9:10 a.m. Eastern Time - Stifel Nicolaus Annual Healthcare Conference, Four Seasons Hotel, Boston, MA
- Thursday, September 12, 2013, at 8:35 a.m. Eastern Time
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com . Archived webcasts will remain available on the Company's website for fourteen (14) days following each presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. Vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, is now being solely developed by GSK and is currently in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as CCX872, a CCR2 inhibitor, and CCX507, an inhibitor of CCR9, both of which are in Phase I clinical testing. ChemoCentryx also has several programs in advanced preclinical development.
CCXI-G
Source: ChemoCentryx, Inc.
ChemoCentryx: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 Media: Susan Kinkead Kinkead Communications, Inc. 415-751-3611 Investors: Caitlyn Murphy Burns McClellan 212-213-0006
